Day: February 5, 2025

CONTINUED STRONG EARNINGS MOMENTUM IN 2024  CASA AND CAG STATED AND UNDERLYING DATA Q4-2024             CRÉDIT AGRICOLE S.A.   CRÉDIT AGRICOLE GROUP    Stated   Underlying     Stated   UnderlyingRevenues   €7,092m+17.4% Q4/Q4   €7,116m+18.2% Q4/Q4     €9,817m+11.9% Q4/Q4   €9,840m+13.4% Q4/Q4Expenses   -€3,917m+5.6% Q4/Q4   -€3,878m+4.4% Q4/Q4     -€5,863m+3.2% Q4/Q4   -€5,824m+2.4% Q4/Q4Gross Operating Income   €3,175m+36.2% Q4/Q4   €3,238m+40.4% Q4/Q4     €3,954m+28.0% Q4/Q4   €4,017m+34.3% Q4/Q4Cost of risk   -€594m+35.0% Q4/Q4   -€594m+35.0% Q4/Q4     -€867m+13.9% Q4/Q4   -€867m+13.9% Q4/Q4Net income group share   €1,689m+26.6% Q4/Q4   €1,730m+32.8% Q4/Q4...

Regulated information Intermediate declaration by the Board of Directors Ieper, Belgium – February 5th, 2025, 07.00 hrs CETDear, Please find herewith the link to our most recent press release: https://www.melexis.com/en/news/2025/financial/melexis-q4-2024-resultsAttachmentPR_ENG_Melexis_Q4 2024

Allschwil, Switzerland, February 05, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today that the sales of the antifungal Cresemba® (isavuconazole) in Japan exceeded the threshold triggering the first sales milestone payment from its partner Asahi Kasei Pharma (AKP), amounting to approximately CHF 1.2 million. David Veitch, Chief Executive Officer of Basilea, said: “Japan is a key market with significant growth potential for Cresemba. The achievement of the first sales milestone already in the second year of commercialization is a testament of the commercial capability of our partner AKP in this important market. The strong sales ramp-up in the early stage of its life cycle in Japan underscores...

Nasdaq CopenhagenLondon Stock ExchangeEuronext DublinOther stakeholders 5 February 2025Ringkjøbing Landbobank’s annual report for 2024 The bank’s board of directors and general management today approved the annual report for 2024. For 2024, a net profit at the top of the announced expectations for the year is realized with DKK 2,301 million, corresponding to an increase of 7% compared to 2023. The bank is very satisfied with this development.Core earnings(DKK million) 2024 2023 2022 2021 2020Total core income 4,068 3,828 2,862 2,433 2,179Total expenses and depreciation 1,044 963 891 817 788Core earnings before impairment charges for loans 3,024 2,865 1,971 1,616 1,391Impairment charges for loans etc. +3 -1 -2 -68 -223Core earnings 3,027 2,864 1,969 1,548 1,168Result for the portfolio etc. +62 -7 -69 +7 -9Special...

Equinor (OSE: EQNR, NYSE: EQNR) will on 6 February 2025 commence the first tranche of up to USD 1.2 billion of the share buy-back programme for 2025, as announced at the Capital Market Update 5 February 2025. In this first tranche, shares for up to USD 396 million will be purchased in the market, implying a total first tranche of up to USD 1.2 billion including shares to be redeemed from the Norwegian State. The tranche will end no later than 2 April 2025. Equinor announces a share buy-back programme of up to USD 5 billion for 2025, including shares to be redeemed from the Norwegian State, in order to conclude the two-year programme for 2024 – 2025, announced in February 2024. The share buy-back programme for 2025 will be subject to market outlook and balance sheet strength and be structured into tranches where Equinor will buy back shares...

Key information relating to the proposed cash dividend to be paid by Equinor (OSE: EQNR, NYSE: EQNR) for fourth quarter 2024. Cash dividend amount: 0.37 Announced currency: USD Last day including rights: 14 May 2025 Ex-date Oslo Børs: 15 May 2025 Ex-date New York Stock Exchange: 16 May 2025 Record date: 16 May 2025 Payment date: 28 May 2025 Date of approval: the proposed cash dividend is subject to approval by the annual general meeting of Equinor ASA on 14 May 2025. Other information: The cash dividend per share in NOK will be communicated 22 May 2025. This information is published in accordance with the requirements of the Continuing Obligations and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.

DUBLIN, Feb. 05, 2025 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the pricing of its previously announced underwritten public offering in the United States of 10,000,000 ordinary shares at a public offering price of $15.00 per share for total gross proceeds of approximately $150 million. All of the ordinary shares are being offered by GH Research PLC. The offering is expected to close on February 6, 2025, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 ordinary shares at the public offering price, less underwriting discounts and commissions. Cantor, Stifel...

32% Increase in the Indicated Resource to 1,538,000 Ounces of Gold 95% Increase in the Inferred Resource to 458,000 Ounces of Gold TORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) — McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) is providing minor corrections to yesterday’s press release. Please note that the resource statements remain unchanged. The corrections are related to Table 2 numbers, specifically the percentage differences between 2021 and December 2024. In addition, the price of gold used in 2021 was $1,725, not $1,750 (in the third paragraph) and the recovery rate for 2021 was 85%, not 90% (in the Footnotes to Tables 1-3). McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) is pleased to report a significant increase in the estimated gold (Au) resources at the Fox Complex’s Grey Fox deposit to December 31st, 2024, compared to the last estimate...

TORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) — Constellation Software Inc. (TSX: CSU) and Topicus.com Inc. (TOI.V) today announced that Topicus’ subsidiary, Yukon Niebieski Kapital B.V. (“Yukon”), has entered into a share purchase agreement with Asseco Poland S.A. (the “Company”) and the Adam Góral Family Foundation (“AG”) for Yukon’s acquisition of 12,318,863 treasury shares held by the Company. These shares represent 14.84% of the Company’s share capital and will be purchased at a price of PLN 85 per share (the “Treasury Shares Purchase Agreement“). The completion of the Treasury Shares Purchase Agreement remains subject to obtaining relevant regulatory and antitrust approvals. This transaction follows Topicus.com Inc.’s announcement on January 31, 2025, regarding its purchase of 9.99% of the issued shares...